Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in mean Total Improvement Score (TIS) over placebo at Week 52. Improvements were sustained from Week 4 onward, even through steroid tapering.
In IMNM, the primary endpoint was met with a 14.8-point improvement over placebo, while DM showed a similar 14.5-point benefit, though statistical significance was missed in that smaller cohort. On August 17, William Blair noted that the results boosted confidence in Vyvgart’s path in DM, sending ARGX shares up 15% to an all-time high. On August 18, RBC Capital raised its price target on Argenx to $1,100 from $1,025, calling the IMNM data a “slam dunk” and projecting rapid commercial uptake given the 20,000 U.S. patient population.
Financial Performance: Scale vs. Regional Licensing
argenx SE (NASDAQ:ARGX) and Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) share clinical success through an exclusive licensing agreement covering Greater China, but their financial profiles remain significantly different in scale and profitability. ARGX delivered blockbuster Q2 2026 results driven by strong global VYVGART momentum, with net product sales reaching $1.516 billion, up 60% year over year. Total operating income reached $1.542 billion, resulting in operating profit of $494 million and net income of $472 million. The company also maintained a strong balance sheet with $5.2 billion in cash and current financial assets.
ZLAB, by contrast, continues to operate as a developing commercial partner with substantially higher cash-burn requirements. Q2 2026 revenue totaled $106.3 million, down 3% year over year, while net product revenue reached $105.8 million. Rising R&D expenses of $61.8 million and SG&A expenses of $72.9 million contributed to an operating loss of $76.5 million and a net loss of $50.8 million. Zai Lab ended the quarter with $717.5 million in cash and short-term investments, highlighting the substantial financial gap between the two partners.
Bull and Bear Cases
Argenx’s bull case is supported by VYVGART’s growing global presence across generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and autoimmune myositis. Its $5.2 billion liquidity position provides substantial financial capacity to expand into additional FcRn-mediated indications without significant dilution risk. However, the bear case centers on the company’s heavy reliance on VYVGART as its primary commercial growth engine, leaving the stock vulnerable to FDA delays or regulatory pushback surrounding separate trials for dermatomyositis (DM).
